StreetAlpha.app
Home › Stocks › RPRX

Royalty Pharma plc (RPRX)

Healthcare
$68.68
▲ +0.23%
LAST CLOSE · NOV 17

Royalty Pharma buys royalty rights on biopharmaceutical medicines and receives payments tied to those drugs' sales. It last closed at $68.68 on Nov 17, up 0.23% on the day. RPRX reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 3 analysts is $71.00 (+3.4% from the last close), with a high of $78.00 and a low of $67.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 6 dark pool prints totaling $4.6M, the largest $1.3M.

AI Auto Pilots
Is RPRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.6B
+11.4% vs a year ago
Net income
$672.5M
−12.0% vs a year ago
EPS (diluted)
$1.53
−12.6% vs a year ago
Operating margin
57.1%
$1.5B operating income
Balance sheet
Cash & equivalents
$513.7M
At Sep 30
Debt
$8.6B
At Sep 30
Buybacks
$261.6M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.3B$2.3BFY2021FY2022: $2.2B$2.2BFY2022FY2023: $2.4B$2.4BFY2023FY2024: $2.3B$2.3BFY2024FY2025: $2.4B$2.4BFY2025

From RPRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 10
2027 · Time not announced
Consensus EPS forecast
$1.53
$960.7M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on RPRX in the past 90 days
Average 12-month target
$71.00
▲ 3.4% upside

Based on 3 analysts who set a price target on RPRX in the past 90 days. The average target is $71.00, with a high of $78.00 and a low of $67.00, compared with the last close of $68.68.

Low $67.00Avg $71.00High $78.00
Blue marker: last close $68.68
Highest target$78.00
Average target$71.00
Lowest target$67.00
Latest rating changes
CitigroupMaintained
Nov 5Buy$78
Morgan StanleyMaintained
Oct 7Buy$67
TD CowenMaintained
Sep 8Buy$68
JP MorganMaintained
Aug 7Buy$62
TD CowenMaintained
Jul 13Buy$65
DateFirmActionRatingPrice target
Nov 5CitigroupMaintainedBuy$78
Oct 7Morgan StanleyMaintainedBuy$67
Sep 8TD CowenMaintainedBuy$68
Aug 7JP MorganMaintainedBuy$62
Jul 13TD CowenMaintainedBuy$65
Loading…

Technical Analysis

RPRX · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 3% above its 20 day and 10% above its 50 day average. It is 20% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 67), near overbought. The nearest support is the Pivot at $68.35, and the nearest resistance the Pivot R1 at $69.09.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNear overbought
VolatilityHigh, 2.2%/day
Key levels
$70.5652 week high+2.7%
$69.77Swing high (Nov 5)+1.6%
$69.09Pivot R1+0.6%
$68.68Last close
$68.35Pivot−0.5%
$67.95Pivot S1−1.1%
$66.8420 day average−2.7%
$64.84Swing low (Nov 4)−5.6%
$61.7750 day average−10.1%
$60.40100 day average−12.1%
$54.89200 day average−20.1%
$37.3152 week low−45.7%
Indicators
RSI (14)67.15Strong, overbought above 70Neutral
MACD2.22Below its signal lineBearish
Stochastic73.6Middle of its rangeNeutral
ADX (14)38.6Trending up
Williams %R-32.8Oversold below −80, overbought above −20Neutral
CCI (20)60.2Oversold below −100, overbought above 100Neutral
Rate of change+3.4%Change over 10 sessionsBullish
ATR (14)$1.55Typical daily range, 2.3% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for RPRX

What happened before

See how RPRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RPRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RPRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RPRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
6
Notional
$4.6M
Largest print
$1.3M
Loading…

RPRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲385 buying vs 267 selling
  • ▲Shares held by funds +2.1%
  • ▲Funds holding +58
  • ▲Superinvestors: 4 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding703645+9.0%
In funds' top 101714+21.4%
Held by funds–––
New / increased110 / 27597 / 292−1.0%
Reduced / sold out219 / 48175 / 45+21.4%
Put/call ratio68.000.06+110961.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RPRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RPRX is in one of them and how their past RPRX trades turned out.

RPRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RPRX in an article yet. Here's the latest on the wider market.

RPRX Congress Trades

All congress trades →
Trades, 12 months
1
Buys
0
0%
Sells
0
0%
People
1
Last filed May 14
Who traded RPRX · since 2024
Latest 3 filings
$1K – $15KTraded Feb 19, 2026Filed May 14, 2026
$100K – $250KTraded Apr 28, 2025Filed Jul 16, 2025
$1K – $15KTraded Nov 14, 2024Filed Dec 5, 2024
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchOther$1K – $15KFeb 19, 2026May 14, 202684 d
Christopher LandauExecutive branchSell$100K – $250KApr 28, 2025Jul 16, 202579 d
Ro KhannaD · CABuy$1K – $15KNov 14, 2024Dec 5, 202421 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Royalty Pharma

Royalty Pharma buys royalty rights on biopharmaceutical medicines, so it receives payments based on the sales of those drugs. It is based in New York. Its portfolio covers more than 35 marketed therapies across areas such as rare diseases, neuroscience, oncology, immunology and diabetes, along with some development-stage product candidates. Its customers are drug developers, from small and midsize biotechnology companies and academic or research institutions to large global pharmaceutical companies that sell the medicines.

Headquarters
New York, NY